Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: Results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: Results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Abstract OBJECTIVE: To assess the efficacy and safety of terguride, a partial dopamine agonist, in patients with fibromyalgia syndrome (FMS). METHODS: In a 12-week, multicenter, double-blind, placebo-controlled, parallel-group study, 99 patients were randomized at a ratio of 2 to 1 to receive terguride or placebo. Over 21 days, the dosage was titrated to a maximum daily dose of 3 mg of terguride or placebo, and this fixed dosage was continued over 9 weeks. The primary efficacy variable was the intensity of pain (100-mm visual analog scale). Secondary efficacy variables included the Fibromyalgia Impact Questionnaire (FIQ) score, the tender point score (TPS), and the Hamilton Depression Scale (HDS) score. During the study, patients were evaluated for the presence of cervical spine stenosis by magnetic resonance imaging (MRI). RESULTS: No significant differences in the change in pain intensity, FIQ score, TPS, or HDS score between baseline and 12 weeks were observed in the terguride group as compared with the placebo group. Cervical spine stenosis was detected in 22% of the patients. Only patients with cervical spine stenosis responded to terguride treatment. FIQ scores improved significantly (per-protocol analysis), and pain intensity, the TPS score, and the HDS score showed a trend toward improvement in the terguride group as compared with the placebo group. Terguride treatment was safe. Only those adverse events already known to be side effects of terguride were observed. Premature termination of the study in patients receiving terguride (26%) occurred predominantly during up-titration and in the absence of comedication for treatment of nausea. CONCLUSION: Terguride treatment did not improve pain, the FIQ score, the TPS, or the HDS score in the total study population. However, a subgroup of patients with cervical spine stenosis seemed to benefit from terguride treatment. 
INTRODUCTION
Fibromyalgia (FMS) is a common yet poorly understood syndrome characterized by chronic widespread pain and tenderness to digital palpation of at least 11 of 18 defined tender points (1) . Studies (2, 3) have demonstrated that FMS patients experience pain differently from the general population and that dysfunctional pain processing plays a role. Central sensitization (3) (4) (5) , dysfunction of inhibitory pathways (6, 7) and altered neurotransmitter concentrations in the brain and the spinal cord (8) (9) (10) are discussed as pathomechanisms and as targets for therapeutic intervention.
A central role of dopaminergic neurotransmission in modulating pain perception (10-13) was proposed. Dopaminergic neurons have been implicated in the control of perception of pain intensity (14) , of anticipation and emotional response to pain (15) , of stress response (11) as well as in spinal modulation of nociceptive input (16) .
The effects of the dopamine agonists pramipexole, ropinirole and rotigotine have or are been studied in FMS in prospective randomized clinical trials (17) (18) (19) . In a 12-week trial in FMS patients receiving uncontrolled doses of concomitant medications that could effect FMS symptoms (17) , dose titration of pramipexole resulted in significant improvements in pain, the Fibromyalgia Impact Questionnaire (FIQ) score and in distinct subscales of the Multidimensional Health Assessment Questionnaire. Based on these results, the evidencebased recommendations for the management of FMS from the European League Against Rheumatism (EULAR) list pramipexole as "should be considered for treatment of FMS" (20) , but emphasize the need for monotherapy trials without concomitant FMS medications for conclusive assessment of effect.
Here we report the results of a randomized, double-blind, placebo-controlled study of terguride in patients with primary fibromyalgia without relevant concomitant medical conditions and excluding concurrent FMS-targeted therapy. Terguride is a partial dopamine agonist and is approved as Teluron ® in Japan for the treatment of hyperprolactinemia (21, 22) .
Since in the randomized, controlled trial of pramipexole FMS patients with comorbid cervical pain or compression were excluded, patients in this study were also assessed for CSS by magnetic resonance imaging (MRI) and possible differences in response to terguride were explored.
PATIENTS AND METHODS

Entry criteria
Patients were screened for eligibility about 6.6 days (range: 2-28 days) prior to treatment start.
Eligible male or female patients met the following criteria: diagnosis of FMS according to the American College of Rheumatology (ACR) 1990 criteria (1), a pain score ≥50 mm on the patient-reported visual analog scale (VAS; 100 mm, (23) ), a tender point score (TPS, (24)) ≥11, age between 18 and 60 years, and a body mass index (BMI) between 18.9 and 30.0.
Patients meeting the following criteria were excluded from the study: known sensitivity to terguride, suffering from relevant liver, kidney, cardiovascular or pulmonary disease, peptic ulcers, Raynaud`s phenomenon, psychosis, encephalomyelitis disseminata, chronic inflammatory diseases, a diagnosis of pituitary tumor representing extrasellar expansion, uncontrolled systolic blood pressure ≥140 mm Hg and a diastolic pressure ≥90 mm Hg, a history of drug or alcohol abuse, or mental impairment. Female patients, who had not used reliable contraception in the cycle before the study, who were pregnant or lactating were excluded. Patients on concurrent FMS-targeted therapy (i.e. antidepressants, selective serotonin reuptake inhibitors (SSRIs), antiepileptics, anxiolytics, muscle relaxants or hypnotics) were excluded, if they did not discontinue therapy at least 6 weeks prior to enrolment, or in the case of antiepileptics, anxiolytics, muscle relaxants or hypnotics discontinued medication ≥10 elimination half-lifes prior to enrolment. Constant treatment with non-steroidal anti-inflammatory drugs (NSAIDs) was allowed.
Study design
The study was carried out as a controlled trial at 1, 2 and 7 centers in Switzerland, the Czech Republic and Germany, respectively. The study protocol, amendments and consent forms were approved by ethics committees and health authorities. A written informed consent was obtained from all patients at the time of enrolment. The trial was carried out in compliance with the Declaration of Helsinki. It was designed as a proof-of-concept study in the treatment of FMS with study medication over a period of 12 weeks. Active drug (0.5 mg terguride) and placebo were supplied as tablets with a subdividing breakmark. The study was conducted according to a randomized, double-blind, placebo-controlled, parallel-group design with a 2:1 ratio of patients being treated with terguride or placebo, respectively. The study consisted of screening, a 3-week up-titration up to 6 tablets per day, a 9-week fixed dose treatment phase and a subsequent 5-day down-titration. Study medication was administered orally in the morning and in the evening. Treatment started (V 0 ) with a half tablet in the evening and was increased after 3 days at constant dose by an additional half tablet in the morning. Thereafter, the daily dose was increased at 1 tablet increments every 3 days up to a maximum of 6 tablets after 21 days (V 3 ). In case of insufficient tolerability, the dose increase could be modified.
After Day 12, a dose increase could be postponed by 3 days in case of suspected drug-related adverse events (AEs). In case of reoccurrence of the AE, the dose increase was cancelled and the patient was maintained on a constant dose of ≥3 tablets throughout the study. Any patient, who did not tolerate 3 tablets per day left the study. From Day 22 until Day 84 (V 12 ), the study medication remained at constant dose. Thereafter, patients were down-titrated over 5 days (V 13 ). Co-medications remained constant from 4 weeks prior to V 0 and throughout the study.
The primary efficacy variable was pain intensity as reported by the patient on the VAS (23).
A standard deviation of pain VAS of 24 and a clinically relevant difference in mean change from baseline to V 12 of the terguride group minus placebo of -17 mm was derived from Holman et al. (7) . Assuming a one-sided significance level of 0.025 and a power of 80% at a 
MRI assessment
A standardized protocol for neuroradiological assessment (including T1-w and T2-w sagittal and axial images) of the cervical spine on 1.5 Tesla MRI units was followed by all centers.
Imaging was allowed at any time during the study. Midline sagittal views of the cervical spinal canal with the neck in neutral alignment were obtained. Centralized readings were performed by a blinded neuroradiologist (M.B.). Sagittal diameters of the spinal canal and the myelon were quantitated and spinal canal stenosis was graded according to modified criteria by Muhle et al. (27) .
Statistical Analysis
Statistical analyses were based on a safety, an intention-to-treat (ITT), and a per-protocol (PP) analysis set. The safety analysis set included all randomized subjects who received at least one dose of study medication. The ITT analysis set included all randomized subjects who received at least one dose of study medication and who provided a valid assessment of the primary variable at baseline and at least one post-baseline assessment. The PP analysis set excluded subjects with major protocol deviations and subjects who did not complete V 12 for reasons definitely not related to study medication.
Continuous variables were summarized by numbers of observations and arithmetic mean, standard deviation (SD), standard error mean (SEM) and 95% confidence interval (CI) or median, minimum, and maximum, respectively. Categorical data were described using absolute and relative frequencies. Efficacy was evaluated by comparing the absolute changes on pain VAS in the ITT analysis between treatment groups. The primary efficacy variable was evaluated by Analysis of Covariance (ANCOVA) using the baseline value as covariate.
Analysis of secondary efficacy variables included descriptive summary statistics for FIQ scores and TPS at each time point. Categorical data were compared using the Fisher`s exact test.
For the subgroup analysis patients with no or only partial obliteration of the anterior or posterior subarachnoid space of the cervical spine were allocated to one subgroup. Patients with myelon hyperintensity or cervical cord compression or displacement, were allocated to a second subgroup. The latter subgroup also included patients with complete obliteration of the subarachnoid space (grade 2) in the neutral position, which infers an increased probability of functional relevant stenosis or worsening thereof, during flexion or extension (27) and can significantly impair function of the myelon.
All efficacy analyses were performed in these two subgroups for exploratory purposes and pvalues < 0.05 were considered significant.
The safety evaluations were based on the safety set by treatment groups and included analyses of AEs, safety laboratory measurements, physical examination, blood pressure and pulse rate, ECG, and echocardiogram. Safety data were evaluated by Fischer's exact test.
RESULTS
Characteristics of the study patients
Between February 12, 2007 and February 1, 2008, a total of 118 patients were screened for participation in the study. Thereof, 99 patients were eligible for the study. They were enrolled and randomized to treatment with terguride (n = 65) or placebo (n = 34). All patients were of
Caucasian race and 88 (88.9%) of the patients were female. 77 (77.8%) of the patients were between 41 and 55 years of age. No significant differences in gender, age, height, weight, body mass index (BMI), smoking habits and alcohol consumption between treatment groups were observed (Table 1) . No significant differences in the baseline characteristics of the efficacy parameters between the terguride and placebo group were noted.
The most frequently observed co-morbidities between the treatment groups were comparable.
Ten patients had made prior use of opioids (5 patients) or anxiolytics (5 patients) or the combination of both (1 patient). In 6 patients (terguride: 4, placebo: 2) this was given for treatment of FMS. A single patient in the terguride group had a diagnosis of restless legs syndrome (RLS A total of 47 patients (72.3%) in the terguride group and 32 patients (94.1%) in the placebo group completed the study. Mean daily intake of study medication was 4.7 ± 0.20 (SEM) and 5.5 ± 0.19 (SEM) tablets in the terguride and placebo groups, respectively. The study was prematurely terminated by 16 (24.6%) and 1 (2.9%) patient in the terguride and the placebo group respectively, due to AEs. Furthermore, treatment of 1 patient each in the terguride and placebo group was terminated due to protocol violations.
Efficacy
In the total study population, pain intensity as the primary endpoint showed a mean change (Table 3) , no significant differences between groups for pain VAS, FIQ score and TPS were observed. No treatment-related changes in the HAM-D score were observed during the course of the study between the terguride and placebo-treatment groups (p=0.937).
Subgroup analysis
In 57 patients with no or partial obliteration of the subarachnoid space of the cervical spine, no significant differences on pain VAS (-1 mm, CI: -12 to 9, p=0.795), FIQ score (-2.6, CI: - 
Safety
In total, 61 (93.8%) patients in the terguride group and 27 (79.4%) patients in the placebo group experienced at least one AE. AEs were predominantly of mild or moderate intensity.
No patient experienced a SAE. Patients reported nausea (terguride: 21 (35.6%), placebo: 4 (11.8%)), headache (terguride: 11 (18.6%), placebo: 9 (26.5%)) and insomnia (terguride:
14 (23.7%), placebo: 3 (8.8%)) as the most frequent AEs (Figure 3) . Nausea was noted at significantly higher frequency in the terguride group than in the placebo group (p<0.05).
Other AEs including insomnia, upper abdominal pain, malaise, dyspepsia, vomiting, vertigo, abdominal pain and headache were not significantly different between treatment groups. A total of 21 (35.6%) patients in the terguride group and 6 (17.6%) patients in the placebo group experienced an AE which resulted in a dose reduction or which prevented a further dose were not significantly different between terguride and placebo groups.
Our findings are similar to the results of the study on safety and efficacy of the dopamine agonist ropinirole CR in FMS patients. This study is unpublished, but results are available from public repositories (19) . No improvement in primary or secondary clinical endpoints was observed following ropinirole treatment as compared to placebo. Similarily, according to a recent press release on a Phase IIa study (NCT00464737) of the dopamine agonist rotigotine in FMS the primary endpoint reduction in pain during rotigotine treatment did not reach statistical significance when compared to a control group (31) . In contrast, Holman and Myers (17) reported a significant therapeutic effect in FMS patients with concomitant medication by the dopamine agonist pramipexole.
The apparent discrepancy of findings between the latter study and our study may be due to the differences in study populations, in trial designs and in the pharmacological profiles of the drugs used. For example, patients of the pramipexole trial received multiple comedications including narcotics, antiepileptics, antidepressants, SSRIs, anxiolytics, muscle relaxants or hypnotics making it difficult to accurately discern the therapeutic effect of the study drug. Of note, when analysing the results of this study it needs to be taken into account that only 16 patients with grade 2-4 CSS were identified by MRI and that the assessment of therapeutic effects is based on small group sizes. Nevertheless and despite the large variability in patient oriented scores, a significant decrease of the FIQ score was observed including effects on physical impairment, do work, rested, stiffness, anxiety and depression subscales.
The pathophysiology of spinal stenosis is still under discussion. Besides static factors that lead to canal encroachment, including congenitally narrowed canal, disk bulging, and spondylitic osteophytes, alteration in the spinal vasculature appears to play a role (41) . Drug treatment of spinal stenosis is so far predominantly of symptomatic nature, but therapeutic effects of prostaglandin E1 in patients with lumbar spinal stenosis (42) were recently reported.
Furthermore, promising effects of the 5-HT 2A antagonist sarpogrelate have been observed in patients (43) and animal models of disc herniation or experimentally-induced spinal stenosis (44, 45) . Terguride, in addition to being a dopamine agonist, also acts as a high affinity antagonist on 5-HT 2 receptors as well as a α 2 -adrenolytic agent in functional bioassays (46).
Thus 5-HT 2 antagonism might provide a potential explanation for the therapeutic effects of terguride in patients with CSS.
In this study only AEs already known as side-effects of terguride were observed. They occurred predominantly and transiently during up-titration of terguride. As known from previous clinical experience and as expected for this drug class, nausea was noted as the most frequent terguride-related AE. Premature termination of patients on terguride treatment was observed with nausea, vomiting and dizziness being named as the most frequent causes. The drop-out rate in the terguride group was 26% as compared to 3% in the placebo group. Rather rapid dose escalation, lack of co-medication for control of gastrointestinal side effects in 10 out of 14 drop-outs, and a generally increased sensitivity of FMS patients to AEs of drugs may have contributed hereto. In clinical use peripheral-acting dopamine antagonists (47, 48) are highly effective in improving the tolerability of dopamine agonists without interference of therapeutic effects. Indeed, most patients, who received either domperidon or proton pump inhibitors as co-medication for nausea, completed the study on schedule.
In this study, an increased frequency of insomnia and use of bromazepam or lormetazepam for treatment of insomnia in the terguride treatment group was observed, although there was no significant difference between the treatment groups. The profile of terguride differs in this respect from other dopamine agonists, for which an increased prevalence of sleep attacks (49) in patients with Parkinson`s disease has been noted and which remain a matter of concern in the use of dopamine agonists.
In summary, terguride treatment did not improve pain, FMS intensity or HAM-D score in the total study population. However, a subgroup of patients with CSS seems to benefit from terguride treatment and warrants further studies. Open and closed symbols are means of placebo-treated or terguride-treated patients, respectively. 
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